Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pharmacyte Biotech, Inc. on February 28, 2022, regarding an event that occurred on February 24, 2022. The Company is incorporated in Nevada and its common stock trades on the Nasdaq Capital Market under the symbol "PMCB".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a corporate governance matter rather than financial performance.
Material Changes
The Company received a notification from the Nasdaq Stock Market stating it is no longer in compliance with Nasdaq Listing Rule 5605(b)(1), the Board Independence Rule. This noncompliance resulted from the passing of Mr. Thomas C.K. Yuen, an independent director, on February 13, 2022. Consequently, the Board no longer consists of a majority of independent directors.
Outlook, Risks, and Management Commentary
- Cure Period: Nasdaq has granted the Company a cure period to regain compliance until the earlier of the next annual shareholders' meeting or February 13, 2023. If the next annual meeting is held before August 12, 2022, compliance must be evidenced by August 12, 2022.
- Management Plan: The Company expects to regain compliance by filling Mr. Yuen's vacancy with a new independent director who satisfies the applicable requirements prior to the expiration of the cure period.
- Risk: Failure to regain compliance within the specified timeframe could result in delisting from the Nasdaq Capital Market.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new independent director to ensure compliance with the Nasdaq cure period.
- Monitor the date of the next annual shareholders' meeting to determine the specific deadline for regaining compliance.
- Review the Company's previous Form 8-K filed on February 17, 2022, for details regarding the passing of Mr. Yuen.